Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02893423 · ClinicalTrials.gov registry record · NA
Ropivacaine Transversus Abdominis Plane Blocks for Cesarean Section Analgesia
A NA study, sponsored by Maimonides Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT02893423 is a NA study that was terminated before completion, run by Maimonides Medical Center. The registered enrollment target is 51 participants.
The verdict
NCT02893423, a NA study, was terminated before completion, sponsored by Maimonides Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
With this research the investigators hope to determine the lowest dose of ropivacaine used in transversus abdominis plane (TAP) blocks that can effectively treat pain in women after cesarean section (c-section).
Interventions
- DRUG Ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2013-01-01 |
| Est. Completion | 2016-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02893423
The ClinicalTrials.gov registry entry for NCT02893423 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ropivacaine is the first listed.
NCT02893423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02893423 about?
NCT02893423 is a clinical study titled "Ropivacaine Transversus Abdominis Plane Blocks for Cesarean Section Analgesia". With this research the investigators hope to determine the lowest dose of ropivacaine used in transversus abdominis plane (TAP) blocks that can effectively treat pain in women after cesarean section (c-section).
What is the current status of trial NCT02893423?
This trial is currently terminated. It is a NA study. The enrollment target is 51 participants. The study started on 2013-01-01. Estimated completion is 2016-09-30.
What interventions are being tested in trial NCT02893423?
The interventions under investigation include: Ropivacaine (DRUG).
Who is sponsoring clinical trial NCT02893423?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.